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Introduction: Abnormal toll-like receptor (TLR)3 signaling plays an indispensable role in pathogenesis of both
experimental and human rheumatoid arthritis, and microRNAs (miRNAs) might orchestrate this signaling pathway.
This study was performed to determine the relationship between miR-26a and TLR3 in rat macrophages and to
observe effects of miR-26a mimic on pristane induced arthritis (PIA) in rats.
Methods: Dual luciferase reporter assay was used to validate the direct interaction between miR-26a (a candidate
miRNA to target tlr3 mRNA) and tlr3 3′UTR. MiR-26a regulation on TLR3 gene expression was determined using
RT-qPCR and Western blotting after miR-26a mimics and inhibitors were transfected into rat macrophage line
NR8383 cells. Poly I:C (TLR3 ligand) was used to trigger TLR3 activation, and mRNA expression of its downstream
cytokines interferon (ifn)-β and tumor necrosis factor (tnf )-α was accordingly detected to determine the regulation
of TLR3 signaling. Expressions of TLR3 and miR-26a were detected during rat bone marrow derived macrophage
(BMDM) induction, in pristane stimulated NR8383 cells and spleens from methotrexate (MTX) treated PIA rats. A
miR-26a mimic was administrated intraperitoneally to PIA rats, and arthritis severity was evaluated by macroscopic
or microscopic observations.
Results: Direct target relationship between miR-26a and tlr3 mRNA in rats was confirmed. Modifications of
miR-26a function by transfection of miR-26a mimics and inhibitors exhibited corresponding repression and augmentation
of TLR3 and its signaling downstream cytokine expressions in NR8383 cells. The alteration of miR-26a expression was
negatively related with TLR3 expression during BMDM induction, in pristane-primed NR8383 cells and PIA rat spleens.
Moreover, both abnormal expressions were rescued in MTX treated arthritis rat spleens. The miR-26a mimic
treatment displayed the depression of TLR3 expression and ameliorated the disease severity in the rats with
pristane induced arthritis.
Conclusions: MiR-26a negatively regulates TLR3 signaling via targeting of TLR3 itself in rat macrophages, and this
finding provides a novel insight into abnormal TLR3 overexpression during experimental arthritis.* Correspondence: mengliesu@mail.xjtu.edu.cn; shemin.lu@gmail.com
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Toll-like receptors (TLRs) belong to a member of the
pattern-recognition receptor family that recognizes highly
conserved structural motifs from microbial pathogens
known as pathogen-associated molecular patterns, or from
necrotic and dying cells known as damage-associated mo-
lecular patterns. Stimulation of TLRs by binding with cor-
responding ligands triggers at least two distinct signaling
pathways: an MyD88-dependent pathway and an MyD88-
independent pathway. TLRs are expressed mainly in innate
immunocytes and play a crucial role in defending microbial
invaders. Recently, accumulating data have documented
that TLRs are also an important player in the development
of inflammatory and immune diseases such as rheumatoid
arthritis (RA), asthma, diabetes and atherosclerosis [1,2].
Among TLRs, TLR3 recognizes double-stranded RNA as
its ligand, activates IFN regulatory factor 3 (IRF3) and IRF7
through a specific MyD88-independent signaling cascade
and triggers the expression of target cytokine genes includ-
ing IFN-β and TNF-α [3-5]. Recent studies have demon-
strated that TLR3 is involved in the pathogenesis of virus
infection and autoimmune disorders, especially RA, in
which RA synovial fibroblasts (RASFs) from early-stage
patients highly express TLR3 and react with its ligand
in vitro, suggesting that this pathway is activated early in
the disease process [6,7]. RASFs are activated by stimula-
tion with both synthetic and endogenous TLR3 ligands
such as poly I:C and necrotic RA synovial fluid cells, result-
ing in pro-inflammatory gene expression [8]. The activated
TLR3 pathway could further promote RASFs sustaining B
cell activation in the synovium [9]. In the previous study,
we found that both TLR3 mRNA and protein expressions
are prominently upregulated in splenic macrophages in
rats with pristine-induced arthritis (PIA) and collagen-
induced arthritis (CIA), and downregulation of TLR3 ex-
pression modulates the severity of arthritis [10,11]. TLR3
in the synovium of PIA rats is also overexpressed in an
early and persistent style and the activation of the TLR3
signaling pathway in vivo could aggravate PIA [12]. The
findings indicate that excess and persistent expression of
the TLR3 gene in macrophages and synovial cells could be
responsible for arthritis development.
TLR3, like other TLRs, has long been considered remark-
ably conserved across the taxonomic kingdoms and consti-
tutively expressed by numerous immune cells [13], even
though studies on regulation of the TLR3 signaling pathway
have been widely performed [11,14-16]. Our study and
others have shown that TLR3 expression per se changes
dramatically under certain scenarios and regulation to its
expression is a means to prevent the excess production of
proinflammatory cytokines from its overactivated signaling
pathway. We presume that miRNA as an important regula-
tor participates in orchestrating the gene expression-
relevant TLR3 and its signal molecules.MiRNAs are defined as endogenous approximately 22
nt RNAs that play a crucial regulatory role via binding to
the mRNAs of protein-coding genes to mediate post-
transcriptional repression [17]. Recent studies have mainly
focused on the miRNA roles in TLR signaling molecules
rather than their role in modulating the expression TLR3
itself [18]. For example, miR-223 regulates TLR-triggered
IL-6 and IL-1β production by targeting Signal transducer
and activator of transcription (STAT3) [19] and miR-146
exerts negative feedback regulation of TLRs and cytokine
receptor signaling via targeting IL-1 receptor-associated
kinase (IRAK)1 and TNF receptor-associated factor
(TRAF)6 [20]. Aforementioned research into miRNA is
necessarily profound, and indicates the possibility of
miRNA participating in arthritis via regulation of TLR sig-
naling. However, the direct target interaction between
miRNA and TLR3 has been underestimated, and miRNA
regulation of TLR3 and its signaling during arthritis devel-
opment remains an enigma. The present study was per-
formed to find the potential miRNAs that can target the
TLR3 molecule itself, verifying both the miRNA and
TLR3 expression in macrophages during differentiation
and pristane stimulation, as well as in the spleen of PIA
rats, and observing the effects of an miR-26a mimic on
TLR3 expression and arthritis severity in PIA rats.
Methods
Bioinformatics
The rat tlr3 mRNA sequence was obtained from GenBank
[NM_198791]. TargetScan 6.2 [21] and MiRanda [22,23],
two widely advocated bioinformatic software systems, were
chosen to seek the candidate miRNAs according to the
presence of binding sites in the seed region, efficacy of tar-
geting and probability of conserved targeting. The unani-
mous predictive outcome from two algorithms was used
for further investigation.Dual luciferase assay
A 198-bp-long tlr3 3′UTR element containing the putative-
binding site of miR-26a (miR-26a sequence: 5′-UUCAA
GUAAUCCAGGAUAGGCU-3′) was cloned downstream of
the luciferase gene between the SacI and HindIII sites within
the pMIR-Report™ Luciferase (Ambion, Austin, USA) vector
to construct a pMIR-TLR3 vector. The mutated tlr3 3′UTR
element containing site mutations at numbers 2, 4, and 6
in the putative miR-26a:tlr3 seed-pair region was obtained
using the PCR-directed mutation method and cloned into
the same vector, namely the mutated pMIR-TLR3 vector.
The pRL-TK vector (Promega, Fitchburg, USA) served as a
control. Plasmids were prepared with the EZNA™ Endo-
free Plasmid Maxi Kit (Omega Bio-tek, Norcross, USA).
The constructs were sequenced to prove sequence integrity
(Genscript company, Nanjing, China).
Jiang et al. Arthritis Research & Therapy 2014, 16:R9 Page 3 of 12
http://arthritis-research.com/content/16/1/R9Hela cells cultured in DMEM high glucose medium
(Hyclone, Logan, USA) containing 10% FBS (Hyclone) were
used for dual luciferase reporter assay. Briefly, both the firefly
pMIR-Report™ Luciferase (Ambion) and renilla pRL-TK (Pro-
mega) vectors (90 ng:10 ng per well) were transfected into-
Hela cells (2 × 104 cells per well seeded for 24 h before
transfection) simultaneously with 10 nM miR-26a mimic/
inhibitor (GenePharma, Shanghai, China) or negative control
(NC) using Lipofectamin 2000™ (Invitrogen, Carlsbad, USA)
transfection reagents in a 48-well culture plate. Sequences
from 5′ to 3′ end are listed as follows: NC mimics sense UU
CUCCGAACGUGUCACGUTT, anti-sense ACGUGACA
CGUUCGGAGAATT; miR-26a mimics sense UUCAA
GUAAUCCAGGAUAGGCU, anti-sense CCUAUCCUG
GAUUACUUGAAUU; NC inhibitor CAGUACUUUUGUG
UAGUACAA (2′Ome-modified), miR-26a inhibitor AGC-
CUAUCCUGGAUUACUU GAA (2′Ome-modified).
The lucifease activity was detected using Dual-Luciferase®
Reporter 1000 Assay System (Promega) by a plate-reading
luminometer (Luminoskan ascent 392, Thermo, Waltham,
USA) 24 h after transfection, and the relative luciferase activ-
ity value was achieved against the renilla luciferase control.
Bone marrow-derived macrophage (BMDM) induction
Rat primary bone marrow-derived cells were isolated from
three normal DA rats, and seeded at the density of 2 ×
106/ml in L929-conditioned medium to differentiate into
macrophages as described in Cold Spring Harbor Proto-
cols [24]. Attached cells on days 0, 3 and 6 were harvested
for miR-26a and TLR3 expression analyses.
Pristane stimulation in macrophages
NR8383 cells, a rat macrophage cell-line, were cultured in
F-12 K medium (Sigma-Aldrich, St. Louis, USA) contain-
ing 15% FBS (Hyclone). MiRNA mimics or inhibitors were
transfected using Lipofectamin™ 2000 (Invitrogen). Emul-
sion of pristane (ACROS Organics, New Jersey, USA) was
made by repeated aspiration with medium. For single pris-
tane stimulation, 5 × 105 cells per well were seeded for 24 h
before a 50-μl pristane emulsion was added in the culture
medium (final concentration 1 mM), and harvested after
stimulation for 24 h. Furthermore, NR8383 cells were
incubated with the mimic or inhibitor for 24 h prior to
activation of TLR3 signaling by stimulation of pristane or
poly I:C (TLR3 ligand, 10 μg/ml, Amersham Biosciences,
Amersham, UK) for another 24 h, and then harvested for
analysis. Appropriate mimic and inhibitor dose for trans-
fection was decided by pilots (data not shown), in which
10 nM was found to be sufficient, hence, was chosen for
most of the following procedures.
Pristane-induced arthritis in rats
DA rats were housed under specific pathogen-free con-
ditiona. Eight rats at the age of 8 to 12 weeks wererandomly divided and used in each group. Arthritis was
induced by a single intradermal injection with 150 μl
pristane at the base of the rat’s tail [25]. In methotrexate
(MTX) treated PIA rats, 0.25 mg intraperitoneal (i.p.)
MTX/kg per rat was administered in 200 μl saline on
days 8, 10 and 12, and rats were sacrificed on day 20
after pristane induction [26]. The same volume of saline
was injected into PIA rats to serve as the saline-treated
PIA group. The rats without pristane injection or MTX
treatment served as the control group. Arthritis develop-
ment and severity was monitored every two to four days
by the perimeters of the foot pad, and macroscopic scor-
ing until sacrifice. After sacrifice the spleens were col-
lected and stored at −80°C for RNA quantification.
MiR-26a mimic treatment in pristane induced arthritis rats
MiR-26a miR-Up™ agomir molecule, which was
cholesterol-modified at the 3′ end, with two phos-
phorthioations at the 5′ end and four at the 3′ end, and
methylation for all skeletons, was purchased from the
company (GenePharma, China) and used as a miR-26a
mimic. The NC agomir molecule and solvent saline
were used as controls. All three groups each contained
seven age- and sex-matched DA rats. Arthritis was in-
duced in rats using pristane at day 0 and then rats were
treated with miR-26a mimic, NC mimics or saline
(150 μg/kg, equal to 11.4 nmol/kg molecules dissolved
in saline each time) through i.p. injection four times, on
days 8, 12, 15 and 19. Arthritis severity was scored every
other day using a comprehensive scoring system [25]
until sacrifice, and the perimeters of ankle, foot pad and
body weights were measured every four days. Rats were
sacrificed on day 23 after pristane injection, and ankles
were collected and prepared for H&E staining. Patho-
logical changes included synovitis, joint destruction and
repair and were scored from 0 to 3 for each of the three
parts [10]. Spleens were harvested and stored at −80°C
for RNA and protein detection. Rat plasma was sepa-
rated for determination of TNF-α using the ELISA
method and nitric oxide (NO) detection using the Griess
method [27]. The animal experiment was approved by the
Institutional Animal Ethics Committee, and procedures
also conformed to the Institutional Animal Care and Use
Committee (IACUC) of Xi’an Jiaotong University.
RT-qPCR
A total RNA of 500 ng isolated with Trizol® Reagent (Invi-
trogen) was used in an miRNA-specific stem loop reverse
transcription (RT) reaction for miRNAs, and 5 μg for the
RT reaction using oligo d(T) primer. cDNA was synthe-
sized by RevertAid™ First Strand cDNA Synthesis Kit
(Fermentas). Real-time quantitative PCR (qPCR) was per-
formed by iQ5 system (Bio-rad) with SYBR® Premix Ex
Taq™ II (TaKaRa) for quantification. Triplicates were used
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was normalized by glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and U6 snRNA, respectively. Purity of
PCR products was confirmed using a melting curve, and all
data were analyzed using the 2-ΔΔCt (relative quantification)
method. The information about genes, primer sequences
(synthesized by Genscript company), and annealing tem-
peratures is depicted in Table 1.
Western blotting
Total cell lysates were prepared and subjected to SDS/
PAGE gel according to standard procedures in the Bio-rad
system. GAPDH on the same membrane was used as a
loading control. Rabbit anti-TLR3 antibody (Biosen, Beijing,
China) and mouse anti-GAPDH antibody (Abcam) were
used as the primary antibody, and the signal was further de-
tected using the secondary antibody of goat anti-rabbit or
goat anti-mouse immunoglobulin (Ig)G labeled with
horseradish peroxidase (HRP). Signal intensity was deter-
mined by Supersignal® West Pico kit (Thermo Scientific).TNF-α determination
Cell supernatant and rat plasma were collected, and
TNF-α was determined using the ELISA development
kit (Peprotech, USA). Briefly, 100 μl plasma or super-
natant was added onto the TNF-α antibody-coated
plate and incubated at 25°C for 2 h. After adding the
biotin-conjugated detecting TNF-α antibody and incu-









3′UTR mutation sense 58
3′UTR mutation Antisense
GAPDH [GenBank:NM_017008] Sense 65
Antisense
IFNB [GenBank:NM_019127] Sense 54
Antisense







U6 snRNA [GenBank:K00784] Sense 60
Antisense5,5' tetramethylbenzidin (TMB) was used for development.
The optical density (OD) value was obtained at the wave of
450 nm by multiskan spectrum (Thermo, USA). The
complete medium of F12K + 15% FBS was used as a blank,
and the TNF-α concentration was calculated from the
standard curve, which was obtained using the series dilu-
tion of recombinant rat TNF-α from 3,000 pg/ml to zero.
Statistics
Quantitative data were expressed as mean ± standard error
of the mean (SEM), and statistical analysis of differences
between experimental groups was performed by the
Mann–Whitney U-test. Differences with P-values less than
0.05 were considered as statistically significant.
Results
Putative targeting relationship between miR-26a and
TLR3 in rats was confirmed by dual luciferase reporter
gene assay
Bioinformatics results showed that miR-26a and miR-
340-5p were candidate miRNAs for targeting rat TLR3
(Figure 1A). As it could bind to tlr3 mRNA from diverse
species, including bushbabies, mice, rabbits and armadil-
los, miR-26a was chosen for further investigation.
To confirm whether TLR3 is the target of miR-26a, the
firefly and renilla dual luciferase reporter assay was per-
formed in Hela cells (Figure 1B). Transfecting both miR-
26a mimics and pMIR-TLR3 vector into Hela cells could
lead to a significant reduction (P <0.05) of luciferase activity
by 20% on average compared with the NC mimics or by)


















Figure 1 Putative target relationship between miR-26a and toll-lke receptor (TLR)3 in rats. (A) Schematic diagram of pairing relationship
between miR-26a and tlr3 mRNA 3′UTR in rats. The rat tlr3 mRNA 3′UTR sequence contains a putative binding site of miR-26a analyzed by the
bioinformatics software [28]. (B) Effect of miR-26a mimics/inhibitor on the luciferase activity of pMIR-TLR3 vector. Target relationship between
tlr3 mRNA 3′UTR and miR-26a was analyzed by dual luciferase reporter assay, pMIR-REPORT™ Luciferase vectors with or without tlr3 mRNA 3′UTR
element (pMIR-TLR3 or pMIR empty vectors) were transfected into Hela cells, and pRL-TK vector was used as an internal control reporter in all
conditions for normalization. NC, negative control; pMIR, pMIR-REPORT™ Luciferase vector. Bars represent standard error of the mean (SEM) from
three transfections. Experiments were independently repeated twice. *Statistically significant difference (P <0.05) compared with NC miRNA;
^significant difference compared with vector (Mann–Whitney U-test). (C) Effect of miR-26a mimics on the luciferase activity of wild-type or
mutated pMIR-TLR3 vector. pMIR-REPORT™ Luciferase vector carrying a TLR3 mRNA 3′UTR element with the putative binding site of miR-26a was
transfected into Hela cells (upper panel). Bars represent SEM from three experiments. *Statistically significant difference (P <0.05, Mann–Whitney
U-test). Schematic diagram of pairing relationship between miR-26a and wild-type or mutated pMIR-TLR3 vector indicates that three nucleotides
have been altered in the mutated pMIR-TLR3 vector (lower panel).
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trary, the miR-26a inhibitor significantly elevated (P <0.05)
the luciferase activity of pMIR-TLR3 vector by 70% on aver-
age compared with the NC inhibitor or by 80% compared
with the empty pMIR vector. To further verify this specific
binding, a mutated pMIR-TLR3 vector with a three-
nucleotide mutation in the putative seed-binding site was
constructed and transfected together with miR-26a mimics
and pRL-TK into Hela cells (Figure 1C). Compared with
the mutated pMIR-TLR3 vector, there was a significant re-
duction (P <0.05) of luciferase activity after the wild-type
pMIR-TLR3 vector and miR-26a mimics were transfected
into cells together with the pRL-TK control, suggesting that
miR-26a specifically binds to the 3′ UTR of rat TLR3
mRNA.
MiR-26a could negatively regulate TLR3 signaling by
intervening in miR-26a function in macrophages
NR8383 cells, a macrophage cell line, were transfected
with miR-26a mimics and miR-26a was significantly in-
creased (as much as 4,000 times) respectively, in the
miR-26a mimics group compared with the NC (P <0.05)
or mock group (P <0.05). The cells were transfected withmiR-26a inhibitors and miR-26a expression was sup-
pressed by 99% compared with the NC (P <0.05) or
mock (P <0.05) group, suggesting that a gain or loss of
miR-26a function occurred (Figure 2A). TLR3 mRNA
expression results showed that miR-26a mimics hardly
affected tlr3 mRNA expression, however miR-26a inhibi-
tors were able to raise tlr3 mRNA expression level by
3.7- or 1.9-fold respectively compared with the mock (P
<0.05) or the NC (P <0.05) group (Figure 2B). In the
mean time, western blotting results of TLR3 protein ex-
pression showed that 10nM miR-26a mimics were able to
significantly suppress TLR3 protein expression by approxi-
mately 30% on average compared with the mock (P <0.05)
or the NC group (P <0.05), and 10nM miR-26a inhibitors
sharply increased TLR3 protein expression by 100% com-
pared with the mock (P <0.05) or by 70% compared with
the NC (P <0.05) (Figure 2C). Different doses of miR-26a
mimics were transfected into NR8383 cells to confirm the
translational suppression. Responding to this increasing
miR-26a expression, TLR3 protein expression displayed
dose-dependent inhibition by approximately 30%, 50%
and 70% respectively, compared with the NC group
(Figure 2D).
Figure 2 Effects of miR-26a on toll-like receptor (TLR)3 signaling by gain or loss of miR-26a function in NR8383. (A) Stem loop RT-qPCR
results of miR-26a expression, (B) RT-qPCR results of tlr3 mRNA expression, and (C) western blotting of TLR3 protein expression after 10nM
miR-26a mimics or inhibitor was transfected into NR8383 macrophages for 48 h. (D) Western blotting results of TLR3 protein expression after 0.1,
1.0 and 10.0 nM of miR-26a mimics were transfected into NR8383 cells for 48 h. (E) Western blotting of TLR3 protein expression and (F) RT-qPCR
results of ifn-β and tnf-α mRNA expression in NR8383 and ELISA results of TNF-α protein expression in cell supernatant (G) after incubated with
10 nM mimics and inhibitors for 24 h and poly I:C (PIC, TLR3 ligand, 10 μg/ml) stimulation for another 24 h. U6 snRNA and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were used as internal controls in RT-qPCR for miRNA and mRNA expression detection respectively. Bars represent the standard
error of the mean from three cell experiments. NC, negative control. One representative plot and quantitative data from three independent western
blotting experiments are shown. Ratio indicates the optical intensity of TLR3 protein bands against GAPDH. *Statistically significant differences (P <0.05)
against the NC; ^significant differences against the mock group (Mann–Whitney U-test).
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naling, NR8383 were incubated with 10 nM mimics or in-
hibitors for 24 h prior to activation of TLR3 signaling by
poly I:C stimulation for another 24 h, and then harvested
for expression analysis. After the signaling pathway was
turned on by its ligand, the protein expression of TLR3
and mRNA expression of ifn-β and tnf-α, two specific
downstream cytokines, were detected. The results showed
that miR-26a mimics caused a 60% reduction, whereas in-
hibitors caused a 1.5-fold increase of TLR3 protein on
average compared with both the NC and mock group
(Figure 2E). MiR-26a mimics caused a 60% and 30% re-
duction of ifn-β mRNA compared with the NC (P <0.05)
or mock (P <0.05), and a 100% reduction of tnf-α mRNA
compared with the NC (P <0.05). miR-26a inhibitors
caused a 60% increase of ifn-β mRNA compared with both
(P <0.05) the NC and mock, and a 100% increase of tnf-α
mRNA compared with the NC (P <0.05) (Figure 2F). ELISAresults also showed that the TNF-α protein concentration
in the cell supernatant was also significantly suppressed
after miR-26a mimic treatment compared with the NC (P
<0.05), and enhanced after inhibitor treatment compared
with both the mock and NC groups (both P <0.05)
(Figure 2G).MiR-26a was downregulated and TLR3 was upregulated
during the induction of rat BMDM
MiR-26a and TLR3 expression was monitored after rat
BMDM was induced for 0, 3 and 6 days. Along with
macrophage induction, tlr3 mRNA was upregulated 5-
and 9-fold, whereas the miR-26a expression declined by
60% and 70% respectively on days 3 and 6 compared
with day 0 after BMDM induction (Figure 3A). TLR3
protein expression also increased 2.8- and 3.0-fold on
average during BMDM induction (Figure 3B).
Figure 3 miR-26a and toll-like receptor (TLR)3 expression during bone marrow-derived macrophage (BMDM) induction. (A) RT-qPCR
results of tlr3 mRNA and miR-26a expression and (B) western blotting results of TLR3 protein expression on day (D)0, D3 and D6 during BMDM
induction. Bone marrows were obtained from three DA rats. U6 snRNA and glyceraldehyde-3-phosphate dehydrogenase (gapdh) were used as
internal controls in RT-qPCR for miRNA and mRNA expression detection, respectively. Bars represent the standard error of the mean from three
rats. *Statistically significant differences (Mann–Whitney U-test, P <0.05). One representative plot and quantitative data from three independent
western blotting tests are shown. Ratio indicates the optical intensity of TLR3 protein bands against GAPDH.
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in rat macrophages after pristane stimulation
In pristane-primed NR8383 cells, enhanced expression of
tlr3 mRNA (P <0.05) and protein expression approxi-
mately 2-fold compared with the medium control,
whereas miR-26a expression decreased by 40% on average
(P <0.05) after 24 h pristane stimulation (Figure 4A and
B). The incubation with miR-26a mimics/inhibitors was
performed for a further 24 h and pristane stimulation for
another 24 h to confirm the target repression of TLR3 sig-
naling by miR-26a in macrophages. Successful transfec-
tion was confirmed by miR-26a expression monitored
by RT-qPCR, and the results showed that alteration of
miR-26a function could regulate TLR3 signaling after
pristane stimulation in macrophages. miR-26a mimics
and inhibitors, respectively, caused a 30% reduction in
40% increase of tlr3 mRNA (P <0.05), a 30% reduction
or 60% increase in ifn-β mRNA (P <0.05), and a 45% re-
duction or 2.5-fold increase in tnf-α mRNA (P <0.05)
compared with the NC group (Figure 4C). Both double-
stranded mimics and single-stranded inhibitors of miR-
26a or the NC could activate tlr3 and ifn-β mRNA
compared with the mock (P <0.05). The NC mimics in-
creased, whereas the inhibitors decreased tnf-α mRNA
expression (P <0.05). MiR-26a mimics exhibited corre-
sponding repression of TLR3 protein by 40% and 25%
compared with the NC or mock group, whereas miR-26a
inhibitors increased TLR3 expression 1.6-fold compared
with the NC or mock (Figure 4D). Similarly, TNF-α pro-
tein concentration in the cell supernatant was detected
using ELISA, and the results showed that it was signifi-
cantly suppressed (P <0.05) after miR-26a mimic treat-
ment, and enhanced (P <0.05) after inhibitor treatment
compared with the mock or NC group (Figure 4E).Implication of miR-26a found in PIA rat spleens
The arthritis score (Figure 5A) and foot-pad perimeter
(Figure 5B) in saline-treated PIA rats were significantly dif-
ferent from control or MTX-treated PIA rats, and there
was no statistical difference between MTX-treated PIA and
control rats, suggesting that MTX could abrogate arthritis.
Expression of tlr3 and miR-26a was monitored in PIA rat
spleens and the results showed that tlr3 mRNA expression
was sharply upregulated 3-fold (P <0.01), whereas miR-26a
expression significantly decreased by 60% on average. How-
ever, both tlr3 excess expression and miR-26a reduction
after MTX treatment surprisingly recovered to the levels of
control rats (Figure 5C).
MiR-26a mimic can ameliorate pristine-induced arthritis
in rats
To observe whether miR-26a overexpression in vivo can
influenze arthritis severity, PIA rats were treated with
miR-26a mimic, NC mimics and saline four times until
rats were sacrificed (Figure 6A). The arthritis clinical
score showed that miR-26a could not prevent the occur-
rence of arthritis from the beginning, but could signifi-
cantly restrain the arthritis severity after the third
injection on day 15 till the rats were sacrificed on day 23
(Figure 6B). Ankle (Figure 6C) and food-pad perimeter
(Figure 6D) in the PIA +miR-26a group was significantly
lower than in the PIA + saline or PIA +NC group on day
23, indicating relief of joint-swelling after miR-26a mimic
treatment (Additional file 1). Body weight loss after arth-
ritis was also alleviated (Additional file 1). There was no
significant difference in the organ-/body-weight ratio in
the spleen, inguinal lymph nodes, heart, liver, lung or kid-
ney, indicating therapy in both the NC and miR-26a
miRNA (Additional file 1). Three major pathological
Figure 4 miR-26a and toll-like receptor (TLR)3 expression in rat macrophages after pristane stimulation in vitro. (A) RT-qPCR results of
tlr3 mRNA and miR-26a expression and (B) western blotting results of TLR3 protein expression in NR8383 after stimulated by 1 mM pristane emulsion
for 24 h. (C) RT-qPCR results of miR-26a, tlr3, ifn-β and tnf-α mRNA expression, (D) western blotting results of TLR3 protein expression in NR8383 and
(E) ELISA results of TNF-α protein expression in the cell supernatant after incubation with 10 nM mimics and inhibitors for 24 h and 1 mM pristane
stimulation for another 24 h. U6 snRNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as internal controls in RT-qPCR for miRNA
and mRNA expression detection, respectively. Bars represent the standard error of the mean from three experiments. *Statistically significant differences
compared with medium control in (A) and (B). In (C) and (D), *significant differences compared with the negative control miRNA group; ^significant
differences compared with the mock group (Mann–Whitney U-test, P <0.05). One representative plot and quantitative data from three independent
western blotting tests are shown. Ratio indicates the optical intensity of TLR3 protein bands against GAPDH.
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http://arthritis-research.com/content/16/1/R9indexes of arthritis in rat ankles, such as synovitis, joint
destruction and joint repair were evaluated, and the results
showed that miR-26a mimics can reduce synovitis in the
PIA +miR-26a group compared with the PIA + saline
group (Figure 6E). There was no significant difference in
the total pathological change or joint destruction and joint
repair (Additional file 1). Meanwhile, rat spleens were har-
vested for RNA and protein expression. MiR-26a expres-
sion in spleens from the PIA +miR-26a group remained
2.5 times higher than in the NC group, even after the last
mimic administration four days previously (Figure 6F).
TLR3 protein expression in the spleen was significantly
suppressed in the PIA +miR-26a group compared with
the PIA +NC group or PIA + saline group (Figure 6G).
The ELISA test also showed that the plasma TNF-α in
PIA +miR-26a rats was lower than in the PIA + saline rats
(Figure 6H). However, there was no significant differencein NO in rat plasma among the groups (Additional file 1).
These results indicated that miR-26a mimic finely con-
trolled TLR3 protein expression and ameliorated arthritis
severity in the PIA rats.
Discussion
To sum up, we predicted miR-26a to be a candidate to tar-
get TLR3 in rats and many other mammals. This putative
targeting relationship between miR-26a and TLR3 was fur-
ther confirmed by dual reporter gene assay. In addition,
miR-26a was verified to be involved in the negative regula-
tion of TLR3 signaling by targeting TLR3 itself in macro-
phages, and modifications of miR-26a function exhibited
corresponding repression or augmentation of TLR3 sig-
naling. In BMDM induction and pristane-stimulated
NR8383 cells, miR-26a reduction was found to be respon-
sible for TLR3 overexpression in rat macrophages. MiR-
Figure 5 miR-26a and toll-like receptor (TLR)3 expression in pristine-induced arthritis (PIA) rats with and without treatment with
methotrexate (MTX). (A) Arthritis scores and (B), foot-pad perimeter in PIA rats with and without treatment with MTX. (C) RT-qPCR results of tlr3
mRNA and miR-26a expression in rat spleens from control, saline-treated PIA and MTX-treated PIA group on day 20 after pristane injection. U6
snRNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as internal controls in RT-qPCR for miRNA and mRNA expression
detection, respectively. Bars represent the standard error of the mean from eight rats used in each group. *Statistically significant differences,
(Mann–Whitney U-test), *PIA plus saline against control; ^PIA plus saline against PIA plus MTX; *,^P <0.05; **,^^P <0.01; ***,^^^P <0.001.
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http://arthritis-research.com/content/16/1/R926a expression was downregulated as tlr3 expression was
decreased in spleens of PIA rats, and both were rescued
after MTX treatment in arthritic rats. MiR-26a mimic
was administrated to PIA rats, and the results showed that
TLR3 protein expression was suppressed, and the arthritis
severity alleviated. Our finding not only discloses the de-
regulation of miR-26a in TLR3 expression, but also offers
a novel and reliable mechanism for abnormal TLR3 over-
expression in experimental arthritis.
According to miRBase [29], an authoritative miRNA
database, miR-26a belongs to one of the miRNA families
broadly conserved with perfectly identical sequences among
vertebrates. In previous reports, miR-26a was on the list of
the top 10% of miRNAs constitutively expressed at a high
level in rat spleen [30], and also found to be considerable
abundant in rat articular cartilage using Solexa sequencing
from our previous study [31]. Its outstanding sufficiency in
major immune organs and cartilage suggests its potential
implication in arthritis development. Previous studies on
miR-26a have provided much evidence of this miRNA asan important regulator in cell proliferation and differenti-
ation. For example, it has been reported that miR-26a plays
a crucial role in regulating mouse hepatocyte proliferation
during liver regeneration [32], and it could also modulate
osteogenic differentiation of human adipose tissue-derived
stem cells by targeting SMAD1 transcription factor [33]. In
addition, upregulated miR-26a promotes myogenesis by
post transcriptional repression of Ezh2, a known suppressor
of skeletal muscle cell differentiation [34].
Mir-26a genes are present on chromosome 3p22.2 and
12q14.1 in the human genome and 8q32 in the rat genome,
and mir-26a itself could be regulated. Microarray-based
miRNA expression profiling found that MYC oncogene
could repress miR-26a [35], Trastuzumab could induce
mir-26a and hence, produces therapeutic actions in human
epidermal growth factor receptor-2 (HER2)-positive breast
cancer cells [36], C/EBP-α can directly activate mir-26a ex-
pression during mechanical stretch, which leads to hyper-
trophy of human airway smooth-muscle cells [37], and
menin, a transcriptional factor has been demonstrated by
Figure 6 Evaluation of miR-26a mimic treatment in pristine-induced arthritis (PIA) rats. (A) A brief scheme for miR-26a mimic treatment in
PIA rats. D, day. (B) Arthritis clinical score curve from the onset day to D23. (C) Mean ankle perimeter and (D) mean foot-pad perimeter of rats.
(E) Quantative data for pathological scores indicating synovitis of arthritis (left panel) and representative H&E staining of rat ankle from each
group (right panel), scale:1.0 mm. (F) miR-26a expression detected by stem loop qRT-PCR in spleens of miR-26a-treated rat spleens. U6 snRNA
was chosen as THE endogenous control. (G) TLR3 protein expression detected by western blotting. Upper bands show representative plots of
toll-like receptor (TLR)3 and endogenous glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control using protein samples from rat spleen.
Lower figure shows the quantitative data for the protein expression ratio calculated using rat spleen protein samples from all groups. (H) TNF-α
protein expression detected by ELISA in rat plasma from all groups. Error bar represents mean ± standard error of the mean of each group (n = 8).
*Statistically significant differences compared with PIA + saline control; ^significant differences compared with PIA + negative control (NC): *,^ P <0.05;
**P <0.01 (Mann–Whitney U-test).
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http://arthritis-research.com/content/16/1/R9chromatin immunoprecipitation (ChIP) to occupy the mir-
26a gene promoter, thus inducing its expression, and con-
firming its role as a positive regulator of mir-26a [38].
In bioinformatics, we found that miR-26a targets TLR3 in
the rat, mouse, rabbit, bushbaby and armadillo; however, the
binding pattern of TLR3:miR-26a disappears in the human
genome with two nucleotide mutations at the seed region
compared with the rat genome. MiR-26a also putatively
targets TLR4 in humans, and in the chimpanzee, rhesus
monkey, horse, elephant, tree shrew and tenrec. This profile
is interestingly complementary among vertebrates available
in the database. Moreover, both TLR3 and TLR4 with an
unique ability to activate IRF-3 and promote the expression
of type I IFN and downstream proinflammatory cytokines
[39], are considered the most overwhelming players in RA
development [6,40,41]. It seems that miR-26a regulation may
transition from TLR3 to TLR4 in many other species. Peer
scientists have long held an opinion that various regulationsystems including miRNAs might not be able to work in the
regulation of TLR expression as in that of most other genes.
However, according to our work, both the regulation of
TLR3 pathway mediators and TLR3 itself by miRNAs should
play a crucial role in TLR3 signaling, which leads to timely
and appropriate control of the proinflammatory events.
TLR3 is intrinsically expressed in rodent macrophages,
hence, in this work we chose the rat macrophage cell line
NR8383 to explore the expression regulation of the TLR3
gene after miR-26a mimics or inhibitors were transfected
into the cells. The negative regulation of the TLR3 gene
from miR-26a was revealed in inactive NR8383 macro-
phages, further in primary macrophages during BMDM
induction, and also in pristine-stimulated NR8383 macro-
phages, confirming that miR-26a could control TLR3
signaling in rat macrophages. In the inactivated phase,
miR-26a mimics hardly affected tlr3 mRNA, yet repressed
its protein by 30%, whereas miR-26a inhibitors increased
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pared with the NC. Inhibitor treatment was found to
cause a much more potent influence on TLR3 than the
mimics. More interestingly, after TLR3 signaling activa-
tion, this negative regulation from miR-26a seemed to be
amplified. After pristane activation, miR-26a mimics re-
pressed tlr3 mRNA by 30% and protein by 40%, and its in-
hibitors also increased tlr3 mRNA by 40% and protein
1.6-fold. There is an explanation for these findings, namely
that miRNAs act as buffers against variation in gene
expression. In this case, endogenous miR-26a might be
sufficient for buffering TLR3 expression fluctuation in
inactivated macrophage so that miR-26a inhibitor treat-
ment exhibits a more powerful function than its mimics.
This evidence supports the leading opinion of more im-
portant roles for miRNAs in conferring robustness to on-
going biological processes [42]. Rescued miR-26a reduction
and TLR3 overexpression in spleens from MTX-treated
PIA rats compared with saline-treated ones also suggested
the implication of miR-26a in rat arthritis. At the end of
this study, the miR-26a administration in PIA rats demon-
strated that miR-26a overexpression can suppress TLR3
protein expression in vivo. Such intervening can also lead
to the alleviation of arthritic conditions, such as joint swell-
ing and synovitis, which suggests the therapeutic potential
of miRNA in TLR overexpression-induced pathological
inflammation.
Conclusion
We found reduction of miR-26a expression in rat macro-
phages during BMDM induction, pristane stimulation and
in spleens of PIA rats in which TLR3 was overexpressed.
MiR-26a-mimic administration also could lead to suppres-
sion of TLR3 protein expression and ameliorate arthritis
in PIA rats. These findings demonstrate that miR-26a reg-
ulates the TLR3 signaling pathway by targeting TLR3 ex-
pression, and implicates miR-26a as a drug target for
inflammatory suppression in arthritis therapy.
Additional file
Additional file 1: Figure showing other arthritis-parameter changes
after miR-26a mimic treatment in pristine-induced arthritis (PIA)
rats. (A) Representative arthritis pictures in rats. (B) Body weight change.
(C) Organ weight/body weight ratio. (D) Total pathological score, score
of joint destruction and repair. (E) Plasma nitric oxide (NO) concentration.
PIA rats were divided into three groups: PIA + saline, PIA + negative control
(NC) and PIA +miR-26a. Error bar represents mean ± standard error of the
mean of each group (n = 8). *Statistically significant difference compared
with PIA + saline control, P <0.05 (Mann–Whitney U-test).
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